Pulse dosing regimen and methods of treatment
US11253520B2 · kind B2 · utility
1Cited by
1References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 24, 2020 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Jan 24, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K45/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.